Both in Biotechnology
IN8bio vs AIM ImmunoTech
Over the past year INAB returned −49.5% and AIM returned −92.0%; their daily moves had a correlation of -0.03.
INAB −49.5% AIM −92.0%Growth of $1, one year, split-adjusted
| Metric | INAB | AIM |
|---|---|---|
| Price | $0.9499 | $0.1607 |
| Market cap | $9.4M | $6.4M |
| Today | +4.38% | 0.00% |
| 1 month | −33.1% | −15.4% |
| 6 months | −41.4% | −68.9% |
| Year to date | −59.4% | −85.8% |
| 1 year | −51.3% | −92.3% |
| Revenue growth (YoY) | — | +4.0% |
| Gross margin | — | 80.8% |
| Net margin | — | −26876.9% |
| P/E (TTM) | — | — |
| Price / sales | — | 67.5× |
| Net cash | $17.8M | $6.3M |
| Dividend yield | — | — |
| Volatility (60d) | 84.5% | 68.1% |
| Short % of float | 0.5% | 3.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).